RenovoRx announced that Shaun Bagai, RenovoRx’s Chief Executive Officer, will present at the Canaccord Genuity 2024 Horizons in Oncology Virtual Conference to be held on April 15, 2024. Bagai will meet with investors and participate in a panel discussion hosted by Bill Maughan, Senior Analyst at Canaccord Genuity. The panel is titled “Delivering High Local Concentrations of Chemotherapy for Solid Tumors.” He will discuss the initial positive interim analysis in the Company’s Phase III TIGeR-PaC clinical trial. The study is evaluating the Company’s lead product candidate, RenovoGem, and proprietary Trans-Arterial Micro-Perfusion therapy platform for the treatment of locally advanced pancreatic cancer. Bagai will also discuss the Company’s plans for 2024 and beyond as well as recent milestones, including the completion of a private placement in January 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
